Loading...

Constance Benson

TitleProfessor
InstitutionUniversity of California San Diego
DepartmentMedicine
Address200 W. Arbor Drive #8208
San Diego CA 92103
Phone619-543-4727
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    The Ohio State University, Columbus, OHMD06/1978Medicine
    Rush University Medical Center, Chicago, IL06/1981Internal Medicine
    Rush University Medical Center, Chicago, IL06/1986Infectious Diseases

    Collapse Overview 
    Collapse Overview
    Constance A. Benson, M.D. is a Professor of Medicine and Global Public Health, Senior Attending Physician, and the Vice Chair for Education and ID Training Program Director for the Division of Infectious Diseases and Global Public Health at University of California, San Diego. She is also the Director of the UCSD Antiviral Research Unit (AVRC), the Principal Investigator (PI) of the UCSD CD4 Collaborative HIV Clinical Trials Unit (CTU) and the Clinical Research Site (CRS) Leader for the UCSD AVRC HIV Clinical Research Site. Dr. Benson received her M.D. degree, Cum Laude from The Ohio State University College of Medicine in 1978, completed her residency in Internal Medicine and a fellowship in Infectious Diseases at Rush University Medical College in Chicago in 1986 after serving three years on active duty in the U.S. Navy as an internist. She was recruited to the faculty of Rush University in the Division of Infectious Diseases in 1986; to the Division of Infectious Diseases at the University of Colorado at Denver in 1997; and to the Division of Infectious Diseases at UCSD in 2005.

    Dr. Benson is an internationally-recognized researcher and clinician working in the fields of HIV and TB clinical and translational investigation since 1984. From 1995 to 2003, Dr. Benson served as the Vice Chair and led the Scientific Agenda Steering Committee, and from 2003 to 2010 served as the Principal Investigator and Chair of the Executive Committee of the NIH/NIAID AIDS Clinical Trials Group (ACTG) Network. The ACTG Network, originally established in 1987, is a multicenter, multinational, therapeutic clinical and translational investigation network with research sites in 13 countries. During her 15 years in the leadership of the ACTG network, and under her scientific and administrative direction, the ACTG expanded its HIV therapeutic research activities to establish international clinical research sites in countries most affected by the HIV/AIDS epidemic, including South Africa, Uganda, Zambia, Botswana, Malawi, Zimbabwe, Tanzania, Kenya, Haiti, Brazil, Peru, India, and Thailand. She oversaw the establishment, training and development of virology, immunology, and pharmacology research laboratories in the US and at international sites, a pharmacogenomics research effort and DNA specimen repository in both the US and internationally for use in HIV-related genomics research, and developed site laboratory capacity to conduct sophisticated diagnostic testing for HIV, tuberculosis, fungal infections and other infectious complications of HIV/AIDS to support ACTG Network trials. She further led the expansion of the ACTG Network activities to include investigational interventions to treat hepatitis B and C and tuberculosis in both mono- and co-infected individuals as part of the network’s scientific agenda. Currently, as the PI of the UCSD CD4 Collaborative CTU and Director of the UCSD Antiviral Research Center, she manages an extensive portfolio of clinical and translational research projects, grants, and contracts, and oversees the conduct of multiple national and international multicenter clinical trials in the fields of HIV/AIDS, viral hepatitis, influenza, tuberculosis and other HIV-related opportunistic complications of global health impact. Her own major areas of research interest include Mycobacterium tuberculosis and other non-tuberculous mycobacterial diseases, other HIV-related opportunistic infections, new antiretroviral drug development, and the treatment of HIV infection and its complications in resource-limited international settings. Most recently her research has focused on the treatment and prevention of HIV-associated tuberculosis, and the development of rapid, point-of-care diagnostic assays for resource-limited settings. Dr. Benson also serves as the UCSD co-director for research capacity development for the NIH-sponsored University of Eduardo Mondlane (UEM) Medical Education Partnership Initiative (MEPI) and two D43 training grants led by Dr. Emilia Noormahomed in Maputo, Mozambique and Dr. Robert Schooley at UCSD. Dr. Benson has also served as a member of the NIH Office of AIDS Research Advisory Council (OARAC) from 2000 to 2003 (Chair from 2001 to 2003), numerous NIH ad hoc study sections, on the Scientific Program Committees for the Infectious Disease Society of America (IDSA), the Conference on Retroviruses and Opportunistic Infections (CROI), and the International AIDS Society (IAS), and on the Board of Directors of the International Antiviral Society-USA, the CROI Foundation Board, the Zimbabwe AIDS Treatment Assistance Project Board, and of Christie’s Place (a non-profit organization supporting women and families affected by HIV infection in San Diego). She serves as a reviewer for 12 major medical journals, as Associate Editor for Clinical Infectious Diseases, and lectures frequently both nationally and internationally on topics within her areas of research and clinical expertise. Dr. Benson is a member of the International AIDS Society, the IDSA, the HIV Medicine Association of the IDSA, the International Union against Tuberculosis and Lung Disease, and the American College of Physicians. Her contributions to the field of HIV/AIDS are numerous. To date, she has published more than 225 original manuscripts, invited reviews, and book chapters, mentored more than 50 trainees in their research and clinical training in ID, and maintains active clinical duties as a subspecialist in Infectious Diseases, HIV and Global Health within the UCSD Health System in San Diego.


    Collapse Research 
    Collapse Research Activities and Funding
    A Novel Wireless Ingestible Sensor System for Measurement of Medication Adherence in HIV Treatment and Prevention
    NIH/NIMH R01MH110057Sep 20, 2015 - Jul 31, 2020
    Role: Principal Investigator
    The UCSD CD4 Collaborative Clinical Trial Unit
    NIH/NIAID UM1AI069432Feb 1, 2007 - Nov 30, 2020
    Role: Principal Investigator
    UCSD Department of Medicine HIV/AIDS Clinical Trials Unit
    NIH/NIAID U01AI069432Feb 1, 2007 - Nov 30, 2013
    Role: Principal Investigator
    AIDS Clinical Trials Group Network
    NIH/NIAID U01AI068636Jun 29, 2006 - May 31, 2013
    Role: Principal Investigator
    ADULT ACTG CENTRAL GROUP
    NIH/NIAID U01AI038858Jan 1, 1996 - Dec 31, 2008
    Role: Principal Investigator
    SAN DIEGO AIDS CLINICAL TRIAL UNIT
    NIH/NIAID U01AI027670Jun 30, 1986 - Dec 31, 2006
    Role: Principal Investigator
    General Clinical Research Center
    NIH M01RR000051Dec 1, 1978 - Mar 31, 2010
    Role: Co-Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000827Mar 1, 1974 - Nov 30, 2010
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Benson C, Andersen JW, Macatangay BJC, Mailliard RB, Rinaldo CR, Read S, Bozzolo DR, Purdue L, Jennings C, Keefer MC, Glesby M, Tebas P, Russell AF, Martin J, Annunziato P, Popmihajlov Z, Lennox JL. Safety and Immunogenicity of Zoster Vaccine Live in HIV-Infected Adults with CD4+ Cell Counts Above 200 Cells/mL Virologically Suppressed on Antiretroviral Therapy. Clin Infect Dis. 2018 Mar 26. PMID: 29590326.
      View in: PubMed
    2. Taiwo BO, Marconi VC, Berzins B, Moser CB, Nyaku AN, Fichtenbaum CJ, Benson C, Wilkin T, Koletar SL, Colasanti J, Acosta EP, Li JZ, Sax PE. Dolutegravir plus lamivudine maintain HIV-1 suppression through week 48 in a pilot randomized trial. Clin Infect Dis. 2017 Dec 26. PMID: 29293895.
      View in: PubMed
    3. Benson C, Currier JS, Del Rio C, Gallant JE, Gulick RM, Marrazzo JM, Richman DD, Saag MS, Schooley RT, Volberding PA. A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care. Top Antivir Med. 2017 Dec/Jan; 24(4):142-151. PMID: 28208122.
      View in: PubMed
    4. Erlandson KM, Kitch D, Wester CW, Kalayjian RC, Overton ET, Castillo-Mancilla J, Koletar SL, Benson C, Campbell TB, Robertson K, Lok JJ. The Impact of Statin and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults With Human Immunodeficiency Virus Infection. Clin Infect Dis. 2017 Nov 29; 65(12):2042-2049. PMID: 29020174.
      View in: PubMed
    5. Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, Barr JJ, Reed SL, Rohwer F, Benler S, Segall AM, Taplitz R, Smith DM, Kerr K, Kumaraswamy M, Nizet V, Lin L, McCauley MD, Strathdee SA, Benson C, Pope RK, Leroux BM, Picel AC, Mateczun AJ, Cilwa KE, Regeimbal JM, Estrella LA, Wolfe DM, Henry MS, Quinones J, Salka S, Bishop-Lilly KA, Young R, Hamilton T. Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection. Antimicrob Agents Chemother. 2017 Oct; 61(10). PMID: 28807909.
      View in: PubMed
    6. Virgínia Noormahomed E, Carrilho C, Ismail M, Noormahomed S, Nguenha A, Benson C, Mocumbi AO, Schooley RT. The Medical Education Partnership Initiative (MEPI), a collaborative paradigm for institutional and human resources capacity building between high- and low- and middle-income countries: the Mozambique experience. Glob Health Action. 2017; 10(1):1272879. PMID: 28452653.
      View in: PubMed
    7. Jenks JD, Benson C. Early cerebritis resulting in a first-time seizure in an otherwise healthy young man. Infect Dis Clin Pract (Baltim Md). 2016 Nov; 24(6):e66-e68. PMID: 27840566.
      View in: PubMed
    8. Logan C, Todorof K, Fiorillo SP, Campbell TB, Elder JH, Borok M, Gudza I, Gwanzura L, Ndemera B, Lochhead MJ, Benson C, Schooley RT. Rapid Multiplexed Immunoassay for Detection of Antibodies to Kaposi's Sarcoma-Associated Herpesvirus. PLoS One. 2016; 11(9):e0163616. PMID: 27669509.
      View in: PubMed
    9. Günthard HF, Saag MS, Benson C, del Rio C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding PA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016 Jul 12; 316(2):191-210. PMID: 27404187; PMCID: PMC5012643.
    10. Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, Chen MP, Benator DA, Gordin F, Benson C, Chaisson RE, Villarino ME. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS. 2016 Jun 19; 30(10):1607-15. PMID: 27243774; PMCID: PMC4899978 [Available on 06/19/17].
    11. Godfrey C, Tauscher G, Hunsberger S, Austin M, Scott L, Schouten JT, Luetkemeyer AF, Benson C, Coombs R, Swindells S. A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries. BMC Infect Dis. 2016 06 10; 16:269. PMID: 27287374; PMCID: PMC4901412.
    12. Maartens G, Benson C. Linezolid for Treating Tuberculosis: A Delicate Balancing Act. EBioMedicine. 2015 Nov; 2(11):1568-9. PMID: 26870767; PMCID: PMC4740312.
    13. Massanella M, Gianella S, Schrier R, Dan JM, Pérez-Santiago J, Oliveira MF, Richman DD, Little SJ, Benson C, Daar ES, Dube MP, Haubrich RH, Smith DM, Morris SR. Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and Viral Outcome during Suppressive Antiretroviral Therapy. Sci Rep. 2015 Aug 24; 5:13179. PMID: 26299251; PMCID: PMC4547398.
    14. Labo N, Miley W, Benson C, Campbell TB, Whitby D. Epidemiology of Kaposi's sarcoma-associated herpesvirus in HIV-1-infected US persons in the era of combination antiretroviral therapy. AIDS. 2015 Jun 19; 29(10):1217-25. PMID: 26035321.
      View in: PubMed
    15. Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, Supparatpinyo K, Mohapi L, Gupta A, Benson C, Kim P, Fletcher CV. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. Clin Infect Dis. 2015 Oct 15; 61(8):1322-7. PMID: 26082504; PMCID: PMC4583578 [Available on 10/15/16].
    16. Givens M, Weaver A, Bickman S, Logan C, Noormahomed EV, Patel S, Schooley RT, Benson C, Lochhead MJ. Near patient CD4 count in a hospitalized HIV patient population. Cytometry B Clin Cytom. 2017 Nov; 92(6):451-455. PMID: 25917935.
      View in: PubMed
    17. Dooley KE, Savic RM, Park JG, Cramer Y, Hafner R, Hogg E, Janik J, Marzinke MA, Patterson K, Benson C, Hovind L, Dorman SE, Haas DW. Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers. Antimicrob Agents Chemother. 2015; 59(6):3399-405. PMID: 25824215; PMCID: PMC4432148.
    18. Badaró R, Gonçalves LO, Gois LL, Maia ZP, Benson C, Grassi MF. Leishmaniasis as a Manifestation of Immune Reconstitution Inflammatory Syndrome (IRIS) in HIV-Infected Patients: A Literature Review. J Int Assoc Provid AIDS Care. 2015 Sep-Oct; 14(5):402-7. PMID: 25331225; PMCID: PMC5004440.
    19. Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson C, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014 Oct 07; 161(7):461-71. PMID: 25285539.
      View in: PubMed
    20. Noormahomed EV, Nhacupe N, Mascaró-Lazcano C, Mauaie MN, Buene T, Funzamo CA, Benson C. A cross-sectional serological study of cysticercosis, schistosomiasis, toxocariasis and echinococcosis in HIV-1 infected people in Beira, Mozambique. PLoS Negl Trop Dis. 2014 Sep; 8(9):e3121. PMID: 25188395; PMCID: PMC4154675.
    21. Mocumbi AO, Carrilho C, Aronoff-Spencer E, Funzamo C, Patel S, Preziosi M, Lederer P, Tilghman W, Benson C, Badaró R, Nguenha A, Schooley RT, Noormahomed EV. Innovative strategies for transforming internal medicine residency training in resource-limited settings: the Mozambique experience. Acad Med. 2014 Aug; 89(8 Suppl):S78-82. PMID: 25072585; PMCID: PMC4116633.
    22. Jacobson JM, Wang H, Bordi R, Zheng L, Gross BH, Landay AL, Spritzler J, Routy JP, Benson C, Aberg J, Tebas P, Haas DW, Tiu J, Coughlin K, Purdue L, Sekaly RP. A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy. J Acquir Immune Defic Syndr. 2014 Aug 01; 66(4):399-406. PMID: 24815851; PMCID: PMC4216663.
    23. Marrazzo JM, del Rio C, Holtgrave DR, Cohen MS, Kalichman SC, Mayer KH, Montaner JS, Wheeler DP, Grant RM, Grinsztejn B, Kumarasamy N, Shoptaw S, Walensky RP, Dabis F, Sugarman J, Benson C. HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014 Jul 23-30; 312(4):390-409. PMID: 25038358.
      View in: PubMed
    24. Günthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson C, Burger DM, Cahn P, Gallant JE, Glesby MJ, Reiss P, Saag MS, Thomas DL, Jacobsen DM, Volberding PA. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014 Jul 23-30; 312(4):410-25. PMID: 25038359.
      View in: PubMed
    25. Zheng Y, Hughes MD, Lockman S, Benson C, Hosseinipour MC, Campbell TB, Gulick RM, Daar ES, Sax PE, Riddler SA, Haubrich R, Salata RA, Currier JS. Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens. Clin Infect Dis. 2014 Sep 15; 59(6):888-96. PMID: 24842909; PMCID: PMC4155445.
    26. Weinberg A, Bosch R, Bennett K, Tovar-Salazar A, Benson C, Collier AC, Zolopa A, Gulick RM, Wohl D, Polsky B, Erice A, Jacobson MA. Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS. J Acquir Immune Defic Syndr. 2014 May 01; 66(1):25-32. PMID: 24378728; PMCID: PMC3981937.
    27. Luetkemeyer AF, Kendall MA, Nyirenda M, Wu X, Ive P, Benson C, Andersen JW, Swindells S, Sanne IM, Havlir DV, Kumwenda J. Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs. J Acquir Immune Defic Syndr. 2014 Apr 01; 65(4):423-8. PMID: 24226057; PMCID: PMC3943693.
    28. Masur H, Brooks JT, Benson C, Holmes KK, Pau AK, Kaplan JE. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014 May; 58(9):1308-11. PMID: 24585567; PMCID: PMC3982842.
    29. Noormahomed EV, Mocumbi AO, Preziosi M, Damasceno A, Bickler S, Smith DM, Funzamo C, Aronoff-Spencer E, Badaró R, Mabila F, Bila D, Nguenha A, Do Rosário V, Benson C, Schooley RT, Patel S, Ferrão LJ, Carrilho C. Strengthening research capacity through the medical education partnership initiative: the Mozambique experience. Hum Resour Health. 2013 Dec 05; 11:62. PMID: 24304706; PMCID: PMC3895849.
    30. Wohl DA, Kendall MA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Benson C, Keiser P, van der Horst C, Jacobson MA. The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit. PLoS One. 2013; 8(11):e78676. PMID: 24260125; PMCID: PMC3829816.
    31. Vignesh R, Kumarasamy N, Lim A, Solomon S, Murugavel KG, Balakrishnan P, Solomon SS, Mayer KH, Swathirajan CR, Chandrasekaran E, Pradeep A, Poongulali S, Benson C, French MA. TB-IRIS after initiation of antiretroviral therapy is associated with expansion of preexistent Th1 responses against Mycobacterium tuberculosis antigens. J Acquir Immune Defic Syndr. 2013 Nov 01; 64(3):241-8. PMID: 23774879.
      View in: PubMed
    32. Lok JJ, Hunt PW, Collier AC, Benson C, Witt MD, Luque AE, Deeks SG, Bosch RJ. The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy. AIDS. 2013 Aug 24; 27(13):2101-10. PMID: 24326304; PMCID: PMC3933027.
    33. Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, Swindells S, Benson C, Grinsztejn B, Sanne IM, Havlir DV, Aweeka F. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013 Aug; 57(4):586-93. PMID: 23592830; PMCID: PMC3719885.
    34. Wang R, Bosch RJ, Benson C, Lederman MM. Drug-resistant virus has reduced ability to induce immune activation. J Acquir Immune Defic Syndr. 2012 Dec 01; 61(4):e60-3. PMID: 23138731; PMCID: PMC3499025.
    35. Logan C, Givens M, Ives JT, Delaney M, Lochhead MJ, Schooley RT, Benson C. Performance evaluation of the MBio Diagnostics point-of-care CD4 counter. J Immunol Methods. 2013 Jan 31; 387(1-2):107-13. PMID: 23063690; PMCID: PMC3529779.
    36. Kumarasamy N, Venkatesh KK, Vignesh R, Devaleenal B, Poongulali S, Yepthomi T, Flanigan TP, Benson C, Mayer KH. Clinical outcomes among HIV/tuberculosis-coinfected patients developing immune reconstitution inflammatory syndrome after HAART initiation in South India. J Int Assoc Provid AIDS Care. 2013 Jan-Feb; 12(1):28-31. PMID: 23011868.
      View in: PubMed
    37. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Günthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012 Jul 25; 308(4):387-402. PMID: 22820792.
      View in: PubMed
    38. Eastburn A, Scherzer R, Zolopa AR, Benson C, Tracy R, Do T, Bacchetti P, Shlipak M, Grunfeld C, Tien PC. Association of low level viremia with inflammation and mortality in HIV-infected adults. PLoS One. 2011; 6(11):e26320. PMID: 22073156; PMCID: PMC3206804.
    39. Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PP, Andersen J, Bliven-Sizemore E, Belisle JT, Boom WH, Luetkemeyer A, Campbell TB, Eisenach KD, Hafner R, Lennox JL, Makhene M, Swindells S, Villarino ME, Weiner M, Benson C, Burman W. CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med. 2011 Oct 15; 184(8):972-9. PMID: 21737585; PMCID: PMC3208659.
    40. Lochhead MJ, Todorof K, Delaney M, Ives JT, Greef C, Moll K, Rowley K, Vogel K, Myatt C, Zhang XQ, Logan C, Benson C, Reed S, Schooley RT. Rapid multiplexed immunoassay for simultaneous serodiagnosis of HIV-1 and coinfections. J Clin Microbiol. 2011 Oct; 49(10):3584-90. PMID: 21865431; PMCID: PMC3187301.
    41. Abraham AG, Lau B, Deeks S, Moore RD, Zhang J, Eron J, Harrigan R, Gill MJ, Kitahata M, Klein M, Napravnik S, Rachlis A, Rodriguez B, Rourke S, Benson C, Bosch R, Collier A, Gebo K, Goedert J, Hogg R, Horberg M, Jacobson L, Justice A, Kirk G, Martin J, McKaig R, Silverberg M, Sterling T, Thorne J, Willig J, Gange SJ. Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america. Am J Epidemiol. 2011 Sep 15; 174(6):727-35. PMID: 21813792; PMCID: PMC3202147.
    42. Krishnan S, Schouten JT, Jacobson DL, Benson C, Collier AC, Koletar SL, Santana J, Sattler FR, Mitsuyasu R. Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis. Oncology. 2011; 80(1-2):42-9. PMID: 21606663; PMCID: PMC3121543.
    43. Holmes EC, Ghedin E, Halpin RA, Stockwell TB, Zhang XQ, Fleming R, Davey R, Benson C, Mehta S, Taplitz R, Liu YT, Brouwer KC, Wentworth DE, Lin X, Schooley RT. Extensive geographical mixing of 2009 human H1N1 influenza A virus in a single university community. J Virol. 2011 Jul; 85(14):6923-9. PMID: 21593168; PMCID: PMC3126550.
    44. Ribaudo HJ, Benson C, Zheng Y, Koletar SL, Collier AC, Lok JJ, Smurzynski M, Bosch RJ, Bastow B, Schouten JT. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis. 2011 Apr 01; 52(7):929-40. PMID: 21427402; PMCID: PMC3062545.
    45. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Pappa KA, Woodward WC, Patterson K, Bolivar H, Benson C, Collier AC. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011 Apr 05; 154(7):445-56. PMID: 21320923; PMCID: PMC3430716.
    46. Althoff KN, Gebo KA, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS, Kitahata MM, Eron JJ, Napravnik S, Rourke SB, Gill MJ, Rodriguez B, Sterling TR, Deeks SG, Martin JN, Jacobson LP, Kirk GD, Collier AC, Benson C, Silverberg MJ, Goedert JJ, McKaig RG, Thorne J, Rachlis A, Moore RD, Justice AC. CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? AIDS Res Ther. 2010 Dec 15; 7:45. PMID: 21159161; PMCID: PMC3022663.
    47. Tien PC, Choi AI, Zolopa AR, Benson C, Tracy R, Scherzer R, Bacchetti P, Shlipak M, Grunfeld C. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr. 2010 Nov; 55(3):316-22. PMID: 20581689; PMCID: PMC2955817.
    48. Park D, Qin H, Jain S, Preziosi M, Minuto JJ, Mathews WC, Moser KS, Benson C. Tuberculosis due to Mycobacterium bovis in patients coinfected with human immunodeficiency virus. Clin Infect Dis. 2010 Dec 01; 51(11):1343-6. PMID: 21028986.
      View in: PubMed
    49. Smurzynski M, Wu K, Benson C, Bosch RJ, Collier AC, Koletar SL. Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study. J Acquir Immune Defic Syndr. 2010 Sep; 55(1):117-27. PMID: 20622677; PMCID: PMC2927805.
    50. Lok JJ, Bosch RJ, Benson C, Collier AC, Robbins GK, Shafer RW, Hughes MD. Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS. 2010 Jul 31; 24(12):1867-76. PMID: 20467286; PMCID: PMC3018341.
    51. Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS, Kitahata MM, Justice AC, Gebo KA, Eron JJ, Rourke SB, Gill MJ, Rodriguez B, Sterling TR, Calzavara LM, Deeks SG, Martin JN, Rachlis AR, Napravnik S, Jacobson LP, Kirk GD, Collier AC, Benson C, Silverberg MJ, Kushel M, Goedert JJ, McKaig RG, Van Rompaey SE, Zhang J, Moore RD. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010 Jun 01; 50(11):1512-20. PMID: 20415573; PMCID: PMC2862849.
    52. May S, Gamst A, Haubrich R, Benson C, Smith DM. Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection. J Acquir Immune Defic Syndr. 2010 Feb; 53(2):194-201. PMID: 19770802; PMCID: PMC2915780.
    53. Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, Hogg RS, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Benson C, Collier AC, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Kushel MB, Goedert JJ, McKaig RG, Moore RD. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis. 2009 Nov 15; 49(10):1582-90. PMID: 19845473; PMCID: PMC2871149.
    54. Smith DM, May SJ, Pérez-Santiago J, Strain MC, Ignacio CC, Haubrich RH, Richman DD, Benson C, Little SJ. The use of pooled viral load testing to identify antiretroviral treatment failure. AIDS. 2009 Oct 23; 23(16):2151-8. PMID: 19730348; PMCID: PMC2915784.
    55. Kumarasamy N, Madhavan V, Venkatesh KK, Saravanan S, Kantor R, Balakrishnan P, Devaleenal B, Poongulali S, Yepthomi T, Solomon S, Mayer KH, Benson C, Schooley R. High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis. 2009 Jul 15; 49(2):306-9. PMID: 19522657.
      View in: PubMed
    56. Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009 Apr 10; 58(RR-4):1-207; quiz CE1-4. PMID: 19357635.
      View in: PubMed
    57. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson C, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009 Apr 30; 360(18):1815-26. PMID: 19339714.
      View in: PubMed
    58. Brooks JT, Kaplan JE, Holmes KK, Benson C, Pau A, Masur H. HIV-associated opportunistic infections--going, going, but not gone: the continued need for prevention and treatment guidelines. Clin Infect Dis. 2009 Mar 01; 48(5):609-11. PMID: 19191648.
      View in: PubMed
    59. Smurzynski M, Collier AC, Koletar SL, Bosch RJ, Wu K, Bastow B, Benson C. AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics. HIV Clin Trials. 2008 Jul-Aug; 9(4):269-82. PMID: 18753121; PMCID: PMC2704053.
    60. Wilson CC, Newman MJ, Livingston BD, MaWhinney S, Forster JE, Scott J, Schooley RT, Benson C. Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy. Clin Vaccine Immunol. 2008 Jun; 15(6):986-94. PMID: 18400976; PMCID: PMC2446619.
    61. Gerber JG, Kitch DW, Fichtenbaum CJ, Zackin RA, Charles S, Hogg E, Acosta EP, Connick E, Wohl D, Kojic EM, Benson C, Aberg JA. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr. 2008 Apr 01; 47(4):459-66. PMID: 17971707; PMCID: PMC2788607.
    62. Andrade AC, Ladeia AM, Netto EM, Mascarenhas A, Cotter B, Benson C, Badaró R. Cross-sectional study of endothelial function in HIV-infected patients in Brazil. AIDS Res Hum Retroviruses. 2008 Jan; 24(1):27-33. PMID: 18275345.
      View in: PubMed
    63. McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, Suckow C, Gopalakrishnan G, Benson C, Wohl DA. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS. 2007 Nov 30; 21(18):2473-82. PMID: 18025884.
      View in: PubMed
    64. Al-Harthi L, MaWhinney S, Connick E, Schooley RT, Forster JE, Benson C, Thompson M, Judson F, Palella F, Landay A. Immunophenotypic alterations in acute and early HIV infection. Clin Immunol. 2007 Dec; 125(3):299-308. PMID: 17916441; PMCID: PMC2702986.
    65. Lee D, Benson C, Lewis CE, Grunfeld C, Scherzer R. Prevalence and factors associated with dry skin in HIV infection: the FRAM study. AIDS. 2007 Oct 01; 21(15):2051-7. PMID: 17885295; PMCID: PMC3166536.
    66. Bosch RJ, Bennett K, Collier AC, Zackin R, Benson C. Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy. J Acquir Immune Defic Syndr. 2007 Mar 01; 44(3):268-77. PMID: 17146370.
      View in: PubMed
    67. Landay A, da Silva BA, King MS, Albrecht M, Benson C, Eron J, Glesby M, Gulick R, Hicks C, Kessler H, Murphy R, Thompson M, White AC, Wolfe P, McMillan FI, Hanna GJ. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis. 2007 Mar 01; 44(5):749-54. PMID: 17278071.
      View in: PubMed
    68. Sailer CA, Pott GB, Dinarello CA, Whinney SM, Forster JE, Larson-Duran JK, Landay A, Al-Harthi L, Schooley RT, Benson C, Judson FN, Thompson M, Palella FJ, Shapiro L. Whole-blood interleukin-18 level during early HIV-1 infection is associated with reduced CXCR4 coreceptor expression and interferon- gamma levels. J Infect Dis. 2007 Mar 01; 195(5):734-8. PMID: 17262717.
      View in: PubMed
    69. Mulligan K, Zackin R, Von Roenn JH, Chesney MA, Egorin MJ, Sattler FR, Benson C, Liu T, Umbleja T, Shriver S, Auchus RJ, Schambelan M. Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Endocrinol Metab. 2007 Feb; 92(2):563-70. PMID: 17090640.
      View in: PubMed
    70. Benson C, Vaida F, Havlir DV, Downey GF, Lederman MM, Gulick RM, Glesby MJ, Wantman M, Bixby CJ, Rinehart AR, Snyder S, Wang R, Patel S, Mellors JW. A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086. J Infect Dis. 2006 Nov 01; 194(9):1309-18. PMID: 17041858.
      View in: PubMed
    71. Haas DW, Geraghty DE, Andersen J, Mar J, Motsinger AA, D'Aquila RT, Unutmaz D, Benson C, Ritchie MD, Landay A. Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study. J Infect Dis. 2006 Oct 15; 194(8):1098-107. PMID: 16991084.
      View in: PubMed
    72. Benson C. Structured treatment interruptions--new findings. Top HIV Med. 2006 Aug-Sep; 14(3):107-11. PMID: 16946455.
      View in: PubMed
    73. Tien PC, Benson C, Zolopa AR, Sidney S, Osmond D, Grunfeld C. The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics. Am J Epidemiol. 2006 May 01; 163(9):860-9. PMID: 16524955; PMCID: PMC3170407.
    74. Ellis RJ, Evans SR, Clifford DB, Moo LR, McArthur JC, Collier AC, Benson C, Bosch R, Simpson D, Yiannoutsos CT, Yang Y, Robertson K. Clinical validation of the NeuroScreen. J Neurovirol. 2005 Dec; 11(6):503-11. PMID: 16338744.
      View in: PubMed
    75. Benson C, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep. 2004 Dec 17; 53(RR-15):1-112. PMID: 15841069.
      View in: PubMed
    76. Benson C, van der Horst C, Lamarca A, Haas DW, McDonald CK, Steinhart CR, Rublein J, Quinn JB, Mondou E, Rousseau F. A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. AIDS. 2004 Nov 19; 18(17):2269-76. PMID: 15577539.
      View in: PubMed
    77. Hicks C, King MS, Gulick RM, White AC, Eron JJ, Kessler HA, Benson C, King KR, Murphy RL, Brun SC. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS. 2004 Mar 26; 18(5):775-9. PMID: 15075512.
      View in: PubMed
    78. Haas DW, Wu H, Li H, Bosch RJ, Lederman MM, Kuritzkes D, Landay A, Connick E, Benson C, Wilkinson GR, Kessler H, Kim RB. MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J Acquir Immune Defic Syndr. 2003 Nov 01; 34(3):295-8. PMID: 14600574.
      View in: PubMed
    79. Benson C, Williams PL, Currier JS, Holland F, Mahon LF, MacGregor RR, Inderlied CB, Flexner C, Neidig J, Chaisson R, Notario GF, Hafner R. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis. 2003 Nov 01; 37(9):1234-43. PMID: 14557969.
      View in: PubMed
    80. Hamzeh FM, Benson C, Gerber J, Currier J, McCrea J, Deutsch P, Ruan P, Wu H, Lee J, Flexner C. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. Clin Pharmacol Ther. 2003 Mar; 73(3):159-69. PMID: 12621381.
      View in: PubMed
    81. Schambelan M, Benson C, Carr A, Currier JS, Dubé MP, Gerber JG, Grinspoon SK, Grunfeld C, Kotler DP, Mulligan K, Powderly WG, Saag MS. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr. 2002 Nov 01; 31(3):257-75. PMID: 12439201.
      View in: PubMed
    82. Benson C, Deeks SG, Brun SC, Gulick RM, Eron JJ, Kessler HA, Murphy RL, Hicks C, King M, Wheeler D, Feinberg J, Stryker R, Sax PE, Riddler S, Thompson M, Real K, Hsu A, Kempf D, Japour AJ, Sun E. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis. 2002 Mar 01; 185(5):599-607. PMID: 11865416.
      View in: PubMed